HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $20 price target.
March 18, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reiterates a Buy rating on Entrada Therapeutics with a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Entrada Therapeutics. This endorsement likely boosts investor confidence in TRDA, suggesting a bullish outlook for the stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100